FDA recalls all Nara Organics infant formula after three babies hospitalized with botulism
By
Mélissa Turbot
Summary
On June 13, 2026, the FDA announced a voluntary recall of all Nara Organics infant formula cans after three infants (ages 2-5 months) in California, Pennsylvania, and Washington were hospitalized with confirmed infant botulism. All had consumed this organic formula made in Europe and sold exclusively in the US. No deaths have been reported. The article details affected lots, symptoms to watch for (constipation, weakness, drooping eyelids), and recommended actions for consumers.
Source
Key quotes
· 3 pulledLe 13 juin 2026, la Food and Drug Administration (FDA) annonçait le rappel volontaire de l'intégralité des canettes de lait maternisé Nara Organics.
Trois nourrissons âgés de 2 à 5 mois, résidant en Californie, en Pennsylvanie et dans l'État de Washington, venaient d'être hospitalisés pour un botulisme infantile confirmé.
Aucun décès n'est à déplorer, mais l'affaire
You might also wanna read
36 UK infants ill from contaminated baby formula; Nestle and Danone batches recalled
At least 36 infants in the UK have developed suspected food poisoning symptoms after consuming contaminated baby formula from Nestle and Dan

New E. coli outbreak detected; FDA begins onsite inspections in Nara infant formula botulism outbreak

Recalled Canned Tuna with Botulism Risk Mistakenly Reshipped to Stores in Multiple States
The article reports that canned yellowfin tuna previously recalled due to defective pull tabs that could introduce potentially fatal botulis

Publisher's Platform: Letter to the Committee on Health, Education, Labor and Pensions
The evolution and regulation of infant formula
A brief historical overview of infant formula, tracing its evolution from a 1865 Prussian "soup for infants" to modern FDA-regulated product
FDA Recalls Oranges for Juggling Demonstration
The U.S. Food and Drug Administration recalled three oranges to demonstrate juggling skills, urging consumers to bring the fruits to their o

Comments
Sign in to join the conversation.
No comments yet. Be the first.